Literature DB >> 25593095

Synthesis and in vitro biological evaluation of 2-(phenylcarbamoyl)phenyl 4-substituted benzoates.

Martin Krátký1, Szilvia Bősze2, Zsuzsa Baranyai2, Ildikó Szabó2, Jiřina Stolaříková3, Georgios Paraskevopoulos1, Jarmila Vinšová4.   

Abstract

Based on the previously described antimicrobial activity of salicylanilide derivatives, we designed and synthesized novel 2-(phenylcarbamoyl)phenyl 4-substituted benzoates. The most active salicylanilides were selected for esterification by various 4-substituted benzoic acids. These compounds were evaluated in vitro against Mycobacterium tuberculosis, including multidrug-resistant strains, nontuberculous mycobacteria (Mycobacterium avium and Mycobacterium kansasii), and eight bacterial and fungal strains. We also investigated the cytostatic and cytotoxic actions of the esters. The minimum inhibitory concentrations (MICs) against mycobacteria ranged from 0.125 to 8μM. Interestingly, the drug-resistant strains exhibited the highest susceptibility without any cross-resistance with established drugs. 4-Bromo-2-[4-(trifluoromethyl)phenylcarbamoyl]phenyl 4-nitrobenzoate showed the most potent inhibition with MIC values ranging from 0.25 to 2μM. Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus, were inhibited by two derivatives with MIC values of at least 0.49μM, whereas Gram-negative bacteria and most of the tested fungi did not display any marked susceptibility. Benzoates exhibited no cytotoxicity at concentrations up to 50μM but most caused significant cytostasis with IC50 values lower than 10μM. Some cytotoxicity-based selectivity indexes for drug-susceptible and drug-resistant M. tuberculosis as well as Staphylococci were higher than 100. These values indicate that some of these derivatives are promising candidates for future research.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial activity; Benzoate; Cytostasis; Cytotoxicity; Ester; In vitro activity; Multidrug-resistant tuberculosis; Mycobacterium tuberculosis; Nontuberculous mycobacteria; Salicylanilide

Mesh:

Substances:

Year:  2014        PMID: 25593095     DOI: 10.1016/j.bmc.2014.12.019

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  2 in total

1.  Repurposing salicylanilide anthelmintic drugs to combat drug resistant Staphylococcus aureus.

Authors:  Rajmohan Rajamuthiah; Beth Burgwyn Fuchs; Annie L Conery; Wooseong Kim; Elamparithi Jayamani; Bumsup Kwon; Frederick M Ausubel; Eleftherios Mylonakis
Journal:  PLoS One       Date:  2015-04-21       Impact factor: 3.240

Review 2.  Looking beyond Typical Treatments for Atypical Mycobacteria.

Authors:  Clara M Bento; Maria Salomé Gomes; Tânia Silva
Journal:  Antibiotics (Basel)       Date:  2020-01-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.